Want to see DE:ACT full AI Analyst Report?
Top Page
AlzChem Group AG
(XETRA:ACT)
Select Model
Select Model
Rating:67Neutral
Price Target:
€185.00
▲(3.18% Upside)
Action:Downgraded
Date:07/10/26
The score is driven primarily by strong financial performance—rapid TTM revenue growth, solid margins, and a very conservative balance sheet with zero debt—partly offset by weak recent free-cash-flow conversion. Technical indicators are currently bearish/soft, with the stock below key short-term moving averages and negative MACD, which tempers the otherwise solid fundamental profile. Valuation is reasonable but not cheap, with a mid-20s P/E and a modest dividend yield.
Positive Factors
Revenue Growth
Sustained, large TTM revenue growth indicates material demand expansion and improving market penetration across end markets. Over 2–6 months this durable top-line expansion supports scale economics, greater pricing leverage, and the ability to fund capacity or product development without relying on external finance.
Negative Factors
Weak Free Cash Flow Conversion
Despite strong operating cash flow, near-zero TTM free cash flow implies elevated capex or working-capital absorption. Over the medium term this constrains the company’s ability to self-fund expansion, pay sustained dividends, or build cash buffers unless conversion improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained, large TTM revenue growth indicates material demand expansion and improving market penetration across end markets. Over 2–6 months this durable top-line expansion supports scale economics, greater pricing leverage, and the ability to fund capacity or product development without relying on external finance.
Read all positive factors
AlzChem Group AG (ACT) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.74B
Dividend Yield1.24%
Average Volume (3M)20.69K
Price to Earnings (P/E)25.7
Beta (1Y)0.55
Revenue GrowthN/A
EPS GrowthN/A
CountryDE
Employees1,541
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)6.61
Shares Outstanding10,176,335
10 Day Avg. Volume15,459
30 Day Avg. Volume20,688
Financial Highlights & Ratios
PEG Ratio1.35
Price to Book (P/B)6.11
Price to Sales (P/S)2.79
P/FCF Ratio39.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€201.67Price Target Upside12.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)6.61
Revenue Forecast (FY)€603.98M
AlzChem Group AG Business Overview & Revenue Model
Company Description
AlzChem Group AG operates globally, engaging in the development, production, and distribution of a wide array of chemical products through its subsidiaries. The company's reach extends across Germany, the European Union, the rest of Europe, Asia, ...
How the Company Makes Money
AlzChem makes money primarily by producing and selling specialty chemical products and chemical intermediates to business customers. Revenue is generated through (1) sales of specialty chemicals and intermediates—where customers pay per delivered ...
AlzChem Group AG Earnings Call Summary
Earnings Call Date:Feb 27, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call conveys a positive operational and financial story: the company delivered a record year with strong margin expansion, robust specialty segment performance, improved net profit and a healthy cash position while advancing major growth projects (creatine, nitroguanidine, U.S. site). Near‑term challenges include a weak Basics & Intermediates segment, a planned six‑month furnace shutdown (≈EUR 15m headwind in 2026), FX and energy cost pressure, and sizeable ongoing CapEx that raises timing and funding risks. On balance, the achievements and growth investments materially outweigh the near‑term negatives, positioning the company for meaningful medium‑term upside if projects execute as planned.Positive Updates
Record Annual Results and Sales
Consolidated sales of EUR 562 million (≈ +EUR 8 million YoY). Company states 2025 was the most successful financial year and largely achieved the guidance corridor (~EUR 580m midpoint).
Negative Updates
Basics & Intermediates Segment Weakness
Sales in Basics & Intermediates ≈ EUR 155 million, down ≈EUR 19 million YoY. Segment EBITDA fell to ≈EUR 5.6 million (about half of prior year) and EBITDA margin declined by ~2.6 percentage points to 3.6%. Decline driven by weak European/German steel demand and higher electricity costs.
Read all updates
Q4-2025 Updates
Positive
Negative
Record Annual Results and Sales
Consolidated sales of EUR 562 million (≈ +EUR 8 million YoY). Company states 2025 was the most successful financial year and largely achieved the guidance corridor (~EUR 580m midpoint).
Read all positive updates
Company Guidance
Management guided FY2026 sales of roughly EUR 600 million (≈+7% vs FY2025 sales of EUR 562m) and EBITDA of about EUR 126 million (≈+8%), implying further expansion of the EBITDA margin beyond the FY2025 level of 20.7%; guidance is for organic growth driven by Specialty Chemicals (FY2025 Specialty sales ≈EUR 380m) with Human Nutrition/creatine and Defense volumes (nitroguanidine commissioning mid‑2026 with ramp in Q3/Q4) as key drivers while Basics & Intermediates are expected to remain around FY2025 sales of ≈EUR 155m. The outlook incorporates a planned six‑month carbide furnace shutdown in H1‑2026 (repair ≈EUR 9–10m plus ≈EUR 5m standstill cost, ≈EUR 15m total included). Cash and investment context: FY2025 closed with net cash ≈EUR 31m and an equity ratio of 41.8%; FY2025 operating cash flow benefitted from ~EUR 60m customer grants and ~EUR 20m higher working capital, investing cash flow rose materially for ongoing CapEx, free cash flow for 2026 is expected to be around zero despite higher CapEx, and management has released ~EUR 120m for a creatine expansion (phased commissioning from H2‑2027 with initial annual sales potential in the low three‑digit million range); the nitroguanidine project is sized at roughly EUR 140–150m with ≈EUR 90m of contract liabilities/customer prepayments on the balance sheet.AlzChem Group AG Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 566.09M | 562.12M | 554.23M | 540.65M | 542.22M | 422.29M |
| Gross Profit | 134.54M | 177.59M | 163.08M | 304.07M | 282.72M | 268.34M |
| EBITDA | 113.65M | 109.44M | 103.96M | 81.75M | 68.06M | 61.89M |
| Net Income | 66.82M | 63.46M | 54.08M | 34.62M | 30.05M | 27.59M |
Balance Sheet | ||||||
| Total Assets | 654.48M | 617.68M | 483.83M | 424.68M | 422.86M | 377.67M |
| Cash, Cash Equivalents and Short-Term Investments | 69.35M | 78.20M | 63.15M | 13.92M | 9.62M | 8.73M |
| Total Debt | 0.00 | 44.23M | 52.82M | 62.49M | 100.23M | 55.64M |
| Total Liabilities | 378.41M | 359.45M | 276.36M | 261.12M | 276.91M | 288.10M |
| Stockholders Equity | 276.06M | 256.30M | 205.54M | 161.63M | 144.01M | 87.63M |
Cash Flow | ||||||
| Free Cash Flow | -20.00K | 39.22M | 62.05M | 52.11M | -33.31M | 14.48M |
| Operating Cash Flow | 125.16M | 137.01M | 105.15M | 72.67M | -4.24M | 43.02M |
| Investing Cash Flow | -120.37M | -96.90M | -30.99M | -20.55M | -28.51M | -28.48M |
| Financing Cash Flow | -26.43M | -29.36M | -24.66M | -49.17M | 33.65M | -23.62M |
AlzChem Group AG Technical Analysis
Positive
179.30
Price Trends
173.79
Negative
169.77
Positive
158.23
Positive
Market Momentum
-2.54
Positive
46.06
Neutral
36.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:ACT, the sentiment is Positive. The current price of 179.3 is above the 20-day moving average (MA) of 178.22, above the 50-day MA of 173.79, and above the 200-day MA of 158.23, indicating a neutral trend. The MACD of -2.54 indicates Positive momentum. The RSI at 46.06 is Neutral, neither overbought nor oversold. The STOCH value of 36.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:ACT.
AlzChem Group AG Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | €4.72B | 16.13 | 16.38% | 3.91% | 0.03% | 5.54% | |
67 Neutral | €1.74B | 25.72 | 27.13% | 1.24% | ― | ― | |
64 Neutral | €7.64B | 48.26 | 1.89% | 8.92% | -9.37% | -47.49% | |
63 Neutral | €8.01B | 35.58 | 5.27% | 4.30% | -9.48% | -56.88% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
53 Neutral | €4.57B | -5.60 | -20.12% | 3.75% | ― | ― | |
49 Neutral | €1.29B | -1.96 | -17.77% | 0.59% | -14.31% | -386.04% |
* Basic Materials Sector Average
DE:ACT
AlzChem Group AG
170.00
25.08
17.31%
DE:BNR
Brenntag AG
56.22
1.45
2.65%
DE:EVK
Evonik
16.34
-0.53
-3.15%
DE:FPE
Fuchs Petrolub
33.10
-1.83
-5.24%
DE:LXS
LANXESS
15.00
-11.33
-43.02%
DE:WCH
Wacker Chemie AG
91.25
22.05
31.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.